On Tuesday, Shares of Citigroup Inc (NYSE:C), added 1.53% and closed at $47.75 in the last trading session. The last trading range of the stock ranges between $47.08 and $48.43. The Preferred Stock Committee of the Board of Directors of Citigroup Inc. recently declared dividends on Citigroup’s preferred stock as follows:
– 8.125% Non-Cumulative Preferred Stock, Series AA, payable November 15, 2016, to holders of record on November 4, 2016. Holders of depositary receipts, each representing one-thousandth of a full preferred share, will be paid $0.5078125 for each receipt held.
– 8.40% Fixed Rate/Floating Rate Non-Cumulative Preferred Stock, Series E, payable October 31, 2016, to holders of record on October 20, 2016. Holders of depositary receipts, each representing one-twenty-fifth of a full preferred share, will be paid $42.00 for each receipt held.
– 5.800% Noncumulative Preferred Stock, Series C, payable October 24, 2016, to holders of record on October 13, 2016. Holders of depositary receipts, each representing one-thousandth of a full preferred share, will be paid $0.3625 for each receipt held.
– 5.350% Fixed Rate/Floating Rate Noncumulative Preferred Stock, Series D, payable November 15, 2016, to holders of record on November 4, 2016. Holders of depositary receipts, each representing one-twenty-fifth of a full preferred share, will be paid $26.75 for each receipt held.
JetBlue Airways Corporation (NASDAQ:JBLU), jumped 0.96% and closed at $17.83 in the last trading session. The last trading range of the stock ranges between $17.81 and $18.19. The company’s Market capitalization is $5.91 Billion with the total Outstanding Shares of 324.00 million. JetBlue (JBLU) recently launched its eighth annual Swing for Good Golf Classic fundraising program. The charitable campaign also includes the Bid for Good online auction, powered by Charity Buzz. Since 2008, the Swing for Good and Bid for Good campaign has raised nearly $3.2 million for 20 charitable partners.
Bid for Good features opportunities to win one-of-a-kind experiences such as JetBlue Getaways vacation packages, a once-in-a-lifetime internship with DoSomething.org, a trip to the Boston Red Sox training camp, a JetBlue flight simulator session, access to VIP events and much more. Online bidding takes place September 30 through October 21, 2016.
This year’s beneficiaries include three youth and education-focused non-profit organizations:
DoSomething.org – DoSomething.org empowers young people to take action in their community around various causes. This non-profit returns for the fourth time as a Swing for Good beneficiary.
Together We Rise – JetBlue welcomes Together We Rise for a second year. This non-profit organization is led by young adults who were formerly in foster care and focuses on transforming the way youth navigate America’s foster care system.
Trinity Biotech plc (ADR)(NASDAQ:TRIB), lost -50.27% and closed at $6.46 in the last trading session. The last trading range of the stock ranges between $5.76 and $7.10. During the 52-week trading session the minimum price at which share price traded, registered at $5.76 and reached to max level of $13.68. Trinity Biotech plc (TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, declared recently that it is withdrawing its 510(k) premarket notification submission for the Meritas Troponin-I Test and Meritas Point-of-Care Analyzer.
The company held a meeting with the FDA on Thursday 29 September, in order to obtain an update on the company’s Meritas Troponin submission. At this meeting the FDA asked Trinity to consider withdrawing their submission, because of some concerns they have about the submission. Their primary concerns relate to the device’s operating temperature range and that the Troponin-I clinical performance is not consistent with the clinical performance data presented by the most recently cleared laboratory Troponin device.
Whilst we believe that the Meritas product demonstrates excellent performance for a point-of-care product and is superior to all existing point-of-care Troponin products in the market, we decided yesterday to withdraw the submission. Over the coming weeks we will engage with the FDA to gain a better understanding of the nature of their concerns. However, it is our understanding that in order for any new point-of-care Troponin product to obtain clearance, the FDA will require it to demonstrate performance equivalent to the most recently cleared laboratory based device. Our decision to withdraw is based on the fact that, notwithstanding its excellent performance characteristics, we believe that there is no certainty that this level of performance can be achieved by the Meritas product even with the benefit of further development efforts.